SI1989200T1 - Derivati (4-(benzo(b)tiofen-2-il)-pirimidin-2-il)-amina kot ikk-beta inhibitorji za zdravljenje raka in vnetnih bolezni - Google Patents

Derivati (4-(benzo(b)tiofen-2-il)-pirimidin-2-il)-amina kot ikk-beta inhibitorji za zdravljenje raka in vnetnih bolezni

Info

Publication number
SI1989200T1
SI1989200T1 SI200630446T SI200630446T SI1989200T1 SI 1989200 T1 SI1989200 T1 SI 1989200T1 SI 200630446 T SI200630446 T SI 200630446T SI 200630446 T SI200630446 T SI 200630446T SI 1989200 T1 SI1989200 T1 SI 1989200T1
Authority
SI
Slovenia
Prior art keywords
åthiophen
ikk
pyrimidin
benzo
cancer
Prior art date
Application number
SI200630446T
Other languages
English (en)
Slovenian (sl)
Inventor
Karl Robert Dahnke
Ho-Shen Lin
Chuan Shih
Q May Wang
Bo Zhang
Michael Enrico Richett
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of SI1989200T1 publication Critical patent/SI1989200T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SI200630446T 2005-11-18 2006-11-15 Derivati (4-(benzo(b)tiofen-2-il)-pirimidin-2-il)-amina kot ikk-beta inhibitorji za zdravljenje raka in vnetnih bolezni SI1989200T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73809705P 2005-11-18 2005-11-18
EP06850430A EP1989200B1 (en) 2005-11-18 2006-11-15 [4-(benzo[b]thiophen-2-yl)-pyrimidin-2-yl]-amine derivatives as ikk-beta inhibitors for the treatment of cancer and inflammatory diseases

Publications (1)

Publication Number Publication Date
SI1989200T1 true SI1989200T1 (sl) 2009-12-31

Family

ID=38345605

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200630446T SI1989200T1 (sl) 2005-11-18 2006-11-15 Derivati (4-(benzo(b)tiofen-2-il)-pirimidin-2-il)-amina kot ikk-beta inhibitorji za zdravljenje raka in vnetnih bolezni

Country Status (27)

Country Link
US (1) US7547691B2 (enExample)
EP (1) EP1989200B1 (enExample)
JP (1) JP2009516697A (enExample)
KR (1) KR100990771B1 (enExample)
CN (1) CN101309918B (enExample)
AR (1) AR057911A1 (enExample)
AT (1) ATE437873T1 (enExample)
AU (1) AU2006337626B2 (enExample)
BR (1) BRPI0618245A2 (enExample)
CA (1) CA2629336A1 (enExample)
CR (1) CR9947A (enExample)
DE (1) DE602006008187D1 (enExample)
DK (1) DK1989200T3 (enExample)
EA (1) EA014426B1 (enExample)
EC (1) ECSP088456A (enExample)
ES (1) ES2329085T3 (enExample)
IL (1) IL190489A0 (enExample)
MA (1) MA30053B1 (enExample)
NO (1) NO20082594L (enExample)
PE (1) PE20070833A1 (enExample)
PL (1) PL1989200T3 (enExample)
PT (1) PT1989200E (enExample)
SI (1) SI1989200T1 (enExample)
TN (1) TNSN08227A1 (enExample)
TW (1) TW200800201A (enExample)
WO (1) WO2007092095A2 (enExample)
ZA (1) ZA200803940B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE478067T1 (de) 2006-03-31 2010-09-15 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyridine und pyrazine als modulatoren des histamin-h4-rezeptors
BRPI0713187A2 (pt) * 2006-07-20 2012-10-16 Mehmet Kahraman método de inibir rho-quinase, método de tratamento de doença mediada por rho-quinase, composto e composição farmacêutica
US8101628B2 (en) 2006-12-21 2012-01-24 Eli Lilly And Company Imidazolidinonyl aminopyrimidine compounds for the treatment of cancer
SI2125794T1 (sl) * 2006-12-21 2011-02-28 Lilly Co Eli Spojine imidazolidinonil aminopirimidina za zdravljenje raka
WO2008144222A2 (en) 2007-05-16 2008-11-27 Eli Lilly And Company Triazolyl aminopyrimidine compounds
EA016781B1 (ru) 2007-05-16 2012-07-30 Эли Лилли Энд Компани Триазолиламинопиримидиновые соединения
EP2924023A1 (en) 2008-06-30 2015-09-30 Janssen Pharmaceutica NV piperidine und piperazine derivativs
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
KR101123178B1 (ko) * 2009-04-09 2012-06-13 (주)에스메디 2-아릴벤조싸이오펜 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 퇴행성 뇌질환의 진단 또는 치료용 약학적 조성물
KR20120059558A (ko) 2009-08-19 2012-06-08 암비트 바이오사이언시즈 코포레이션 바이아릴 화합물 및 이의 사용 방법
JP5634596B2 (ja) 2010-04-27 2014-12-03 ハチソン メディファーマ リミテッド ピリミジニルインドール化合物
US20140194383A1 (en) 2011-04-07 2014-07-10 Cornell University Monomers capable of dimerizing in an aqueous solution, and methods of using same
US9245773B2 (en) 2011-09-02 2016-01-26 Taiwan Semiconductor Manufacturing Company, Ltd. Semiconductor device packaging methods and structures thereof
CN103159742B (zh) * 2011-12-16 2015-08-12 北京韩美药品有限公司 5-氯嘧啶类化合物及其作为egfr酪氨酸激酶抑制剂的应用
AU2013216935C1 (en) 2012-02-08 2017-12-14 John Emmerson Campbell Heteroaryl compounds and methods of use thereof
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
TWI659021B (zh) 2013-10-10 2019-05-11 亞瑞克西斯製藥公司 Ｋｒａｓ ｇ１２ｃ之抑制劑
CN105085434B (zh) * 2014-05-09 2018-02-09 上海特化医药科技有限公司 硫乙拉嗪或其中间体的制备方法
US9796699B2 (en) 2015-11-03 2017-10-24 Janssen Pharmaceutica Nv Substituted 2-[3-(1-methyl-piperidin-4-yl)-propylamino]-pyrimidine-5-carboxylic acids and amides and methods of making the same
BR112019001407A2 (pt) 2016-07-29 2019-07-09 Sunovion Pharmaceuticals Inc. compostos e composições e usos dos mesmos
SG10202100724UA (en) 2016-07-29 2021-03-30 Sunovion Pharmaceuticals Inc Compounds and compositions and uses thereof
EP3573971A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
EP3573954A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
US11136308B2 (en) 2017-01-26 2021-10-05 Araxes Pharma Llc Substituted quinazoline and quinazolinone compounds and methods of use thereof
WO2018140599A1 (en) * 2017-01-26 2018-08-02 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
WO2018218069A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant kras, hras or nras
CN110869358A (zh) 2017-05-25 2020-03-06 亚瑞克西斯制药公司 Kras的共价抑制剂
MX2020000523A (es) 2017-08-02 2020-08-20 Sunovion Pharmaceuticals Inc Compuestos de isocromano y usos de los mismos.
BR112021001709A2 (pt) 2018-08-01 2021-05-04 Araxes Pharma Llc compostos espiro heterocíclicos e métodos de uso dos mesmos para o tratamento de câncer
JP7703449B2 (ja) 2019-03-14 2025-07-07 スミトモ・ファーマ・アメリカ・インコーポレイテッド イソクロマニル化合物の塩およびその結晶体、ならびにそれらの製造方法、治療用途および医薬組成物
US20260116871A1 (en) * 2024-10-24 2026-04-30 Fujian Haixi Pharmaceuticals Co., Ltd. Tyrosine Kinase Inhibitors and Uses Thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989011279A1 (en) * 1988-05-16 1989-11-30 Georgia State University Foundation, Inc. Nucleic acid interacting unfused heteropolycyclic compounds
GB0308466D0 (en) * 2003-04-11 2003-05-21 Novartis Ag Organic compounds
AU2005316312B2 (en) 2004-12-17 2009-10-22 Amgen, Inc. Aminopyrimidine compounds and methods of use

Also Published As

Publication number Publication date
ATE437873T1 (de) 2009-08-15
ZA200803940B (en) 2009-09-30
AR057911A1 (es) 2007-12-26
US7547691B2 (en) 2009-06-16
ES2329085T3 (es) 2009-11-20
DE602006008187D1 (de) 2009-09-10
US20080306082A1 (en) 2008-12-11
ECSP088456A (es) 2008-06-30
PT1989200E (pt) 2009-10-12
WO2007092095A3 (en) 2007-11-08
KR20080059451A (ko) 2008-06-27
CR9947A (es) 2008-11-28
NO20082594L (no) 2008-06-10
EA014426B1 (ru) 2010-12-30
DK1989200T3 (da) 2009-11-09
JP2009516697A (ja) 2009-04-23
EP1989200B1 (en) 2009-07-29
IL190489A0 (en) 2008-11-03
WO2007092095A2 (en) 2007-08-16
PL1989200T3 (pl) 2009-12-31
AU2006337626A1 (en) 2007-08-16
CA2629336A1 (en) 2007-08-16
PE20070833A1 (es) 2007-08-27
AU2006337626B2 (en) 2012-03-22
MA30053B1 (fr) 2008-12-01
CN101309918A (zh) 2008-11-19
EA200801362A1 (ru) 2009-02-27
CN101309918B (zh) 2010-12-29
EP1989200A2 (en) 2008-11-12
AU2006337626A8 (en) 2008-06-19
TW200800201A (en) 2008-01-01
BRPI0618245A2 (pt) 2011-08-23
KR100990771B1 (ko) 2010-10-29
TNSN08227A1 (en) 2009-10-30

Similar Documents

Publication Publication Date Title
IL190489A0 (en) [4-(benzo[b] thiophen-2-yl) pyrimidin-2yl]-amine derivatives as ikk-beta inhibitors for the treatment of cancer and inflammatory diseases
MX2009006706A (es) Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos.
PL2120932T3 (pl) Indazolowe pochodne jako inhibitory kinazy do leczenia raka
IL184934A0 (en) 4-oxoquinazoline-3-yl-benzamide derivatives for the treatment of cytokine diseases
IL186749A0 (en) Dihydrothienopyrimidines for the treatment of inflammatory diseases
IL195731A0 (en) Pyrimidine derivatives useful in the treatment of cancer
IL198596A0 (en) Thienopyrimidinones for treatment of inflammatory disorders and cancers
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
ZA200710598B (en) Treatment of inflammatory conditions
LT2478907T (lt) Kompozicijos vėžiui gydyti
IL191832A0 (en) Pyridiazinone derivatives for the treatment of tumours
ZA200806072B (en) Hydantoin derivatives for the treatment of inflammatory disorders
ZA201000075B (en) Purin derivatives for use in the treatment of fab-related diseases
EP2063896A4 (en) KINASEHEMMER FOR THE TREATMENT OF PROLIFERATIVE DISEASES
IL196202A0 (en) Indazole derivatives for the treatment of hsp90-induced diseases
SI2056807T1 (sl) Zdravljenje vnetnih bolezni
IL209730A0 (en) Triazole derivatives useful for the treatment of diseases
IL194425A0 (en) N-oxides of heterocyclic substituted bisarylureas for treating kinase-mediated diseases
ZA201001264B (en) 1-amino-alkylcycohxane derivatives for the treatment of cochleat tinnitus
IL192933A0 (en) Benzoisoindole derivatives for the treatment of pain
IL177455A0 (en) Pyrazoline derivatives useful for the treatment of cancer
GB0605715D0 (en) Treatment of laminitis
IL226363A0 (en) Compounds and methods for treating cancer
HK1123805A (en) [4-(benzo[b]thiophen-2-yl)-pyrimidin-2-yl]-amine derivatives as ikk-beta inhibitors for the treatment of cancer and inflammatory diseases
ZA200708853B (en) Methods of treatment utilizing certain melatonin derivatives